2. Academic Validation
  3. E-Selectin-Binding Peptide-Modified Bovine Serum Albumin Nanoparticles for the Treatment of Acute Lung Injury

E-Selectin-Binding Peptide-Modified Bovine Serum Albumin Nanoparticles for the Treatment of Acute Lung Injury

  • AAPS PharmSciTech. 2019 Jul 30;20(7):270. doi: 10.1208/s12249-019-1403-2.
Yu Liu 1,  Bowen Yang 2 3 4,  Xuan Zhao 1,  Mingrong Xi 5 6 7,  Zongning Yin 8
Affiliations

Affiliations

  • 1 Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, People's Republic of China.
  • 2 Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, 610041, Sichuan, China.
  • 3 Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education, Chengdu, China.
  • 4 Ministry of Education, West China Second University Hospital of Sichuan University Chengdu, Chengdu, Sichuan, People's Republic of China.
  • 5 Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, 610041, Sichuan, China. qmrjzz@126.com.
  • 6 Key Laboratory of Birth Defects and Related Diseases of Women and Children, (Sichuan University), Ministry of Education, Chengdu, China. qmrjzz@126.com.
  • 7 Ministry of Education, West China Second University Hospital of Sichuan University Chengdu, Chengdu, Sichuan, People's Republic of China. qmrjzz@126.com.
  • 8 Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, People's Republic of China. yzn@scu.edu.cn.
PMID: 31363872 DOI: 10.1208/s12249-019-1403-2
Abstract

Currently, there is no specific treatment for acute lung injury (ALI). E-selectin-binding peptide (Esbp), a high-affinity peptide that delivers drugs targeting inflammatory vascular endothelial cells, can bind to E-Selectin and act as a targeting ligand for selective drug delivery. In this study, we coupled the thiol groups of Esbp to the amino groups on the surface of bovine serum albumin (BSA) using succinimidyl iodoacetic acid to make Esbp-modified BSA nanoparticles (BSANPs) at the average ratio of 19.3 μg Esbp to 1 mg BSA. The Esbp-modified BSANPs were spherical in shape and had a particle size of 266.7 ± 2.7 nm, polydispersity index of 0.165 ± 0.02, zeta potential of - 33.64 ± 1.23 mV, encapsulation efficiency of 84.3 ± 2.3%, and drug loading of 6.7 ± 0.32%. The cumulative release rate of dexamethasone-loaded Esbp-modified BSANPs was 51.2% within 12 h, significantly lower than that of 88.2% of free drugs. Moreover, Esbp-modified BSANPs could be uptaken in vitro by activated human umbilical vein endothelial cells and in vivo by the lungs of the established ALI mouse model. These results indicated that our Esbp-modified BSANPs delivery system has characteristics of good targeting ability and biocompatibility and is able to inhibit inflammation. Overall, our Esbp-modified BSANPs delivery system has therapeutic potentials as a new targeting drug system for the treatment of ALI in the future.

Keywords

E-selectin-binding peptide; acute lung injury; bovine serum albumin nanoparticles; dexamethasone; targeting ability.

Figures
Products